JPRN-jRCT1080223173已完成4 期
A Postmarketing Clinical Study of Repaglinide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 117
研究概览
简要总结
Repaglinide in combination with a long-acting insulin improved HbA1c levels without major safety issues.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with type 2 diabetes mellitus who meet the following requirements
- •-Patients who have been on a fixed regimen of diet and exercise therapies
- •-Patients who are on a fixed dosage regimen of long-acting insulin
- •-Patients whose HbA1c level is 7.0% <= HbA1c <= 10.0% and is stable over 4 weeks
- •-Patients aged 20 or older
- •-Outpatients
排除标准
- •Patients with hepatic impairment
- •Patients with renal impairment
- •Patients with cardiac diseases
- •Patients with severe hypertension
研究者
相似试验
已完成
不适用
Efficacy and safety of repaglinide on glycemic control in diabetic patients with chronic renal failure [Diamond study-2]Diabetic patients with chronic renal failureJPRN-UMIN000009166Diamond study group20
已完成
4 期
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-DiabetesDiabetes Mellitus, Type 2NCT00118963Steno Diabetes Center Copenhagen102
已完成
4 期
Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) FailureType 2 Diabetes MellitusNCT01461577Sanofi89
已完成
3 期
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin GlargineDiabetes Mellitus, Type 2NCT00976391GlaxoSmithKline586
已完成
不适用
To evaluate the efficacy and safety of sitagliptin for the long-term treatment of type 2 diabetestype 2 diabetesJPRN-UMIN000038459Department of Diabetes and Metabolism,Tohto Clinic33